Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2008-4-2
pubmed:abstractText
Cancer/testis antigens (CTAs) are considered to be suitable targets for the immunotherapy of human malignancies. It has been demonstrated that in a variety of tumors, the expression of certain CTAs is activated via the demethylation of their promoter CpG islands. In our study, we have shown that while the composite expression of 13 CTAs in 30 human glioma specimens and newly established cell lines from the Japanese population was nearly imperceptible, the DNA-demethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) markedly reactivated CTA expression in glioma cells but not in normal human cells. We quantified the diminished methylation status of NY-ESO-1-one of the most immunogenic CTAs-following 5-aza-CdR treatment by using a novel Pyrosequencing technology and methylation-specific PCR. Microarray analysis revealed that 5-aza-CdR is capable of signaling the immune system, particularly, human leukocyte antigen (HLA) class I upregulation. (51)Cr-release cytotoxicity assays and cold target inhibition assays using NY-ESO-1-specific cytotoxic T lymphocyte (CTL) lines demonstrated the presentation of de novo NY-ESO-1 antigenic peptides on the cell surfaces. In an orthotopic xenograft model, the systemic administration of 5-aza-CdR resulted in a significant volume reduction of the transplanted tumors and prolonged the survival of the animals after the adoptive transfer of NY-ESO-1-specific CTLs. These results suggested that 5-aza-CdR induces the expression of epigenetically silenced CTAs in poorly immunogenic gliomas and thereby presents a new strategy for tumor immunotherapy targeting 5-aza-CdR-induced CTAs.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1097-0215
pubmed:author
pubmed:copyrightInfo
(c) 2008 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
122
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2542-53
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18240144-Adoptive Transfer, pubmed-meshheading:18240144-Analysis of Variance, pubmed-meshheading:18240144-Animals, pubmed-meshheading:18240144-Antigens, Neoplasm, pubmed-meshheading:18240144-Antimetabolites, Antineoplastic, pubmed-meshheading:18240144-Asian Continental Ancestry Group, pubmed-meshheading:18240144-Azacitidine, pubmed-meshheading:18240144-Blotting, Western, pubmed-meshheading:18240144-Brain Neoplasms, pubmed-meshheading:18240144-Chromosome Mapping, pubmed-meshheading:18240144-CpG Islands, pubmed-meshheading:18240144-DNA Methylation, pubmed-meshheading:18240144-Flow Cytometry, pubmed-meshheading:18240144-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18240144-Glioma, pubmed-meshheading:18240144-Histocompatibility Antigens Class I, pubmed-meshheading:18240144-Humans, pubmed-meshheading:18240144-Kaplan-Meier Estimate, pubmed-meshheading:18240144-Male, pubmed-meshheading:18240144-Membrane Proteins, pubmed-meshheading:18240144-Mice, pubmed-meshheading:18240144-Mice, Inbred NOD, pubmed-meshheading:18240144-Mice, SCID, pubmed-meshheading:18240144-Microarray Analysis, pubmed-meshheading:18240144-Promoter Regions, Genetic, pubmed-meshheading:18240144-Reverse Transcriptase Polymerase Chain Reaction, pubmed-meshheading:18240144-T-Lymphocytes, Cytotoxic, pubmed-meshheading:18240144-Testis, pubmed-meshheading:18240144-Transplantation, Heterologous, pubmed-meshheading:18240144-Up-Regulation
pubmed:year
2008
pubmed:articleTitle
The DNA demethylating agent 5-aza-2'-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma.
pubmed:affiliation
Department of Neurosurgery, Nagoya University School of Medicine, Nagoya, Japan. anatsume@med.nagoya-u.ac.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't